Amgen completes Abgenix acquisition
Executive Summary
Amgen has completed its $2.2 bil. acquisition of Abgenix. The deal, inked in December, gives Amgen full ownership of metastatic colorectal cancer treatment panitumumab (1"The Pink Sheet" Dec. 19, 2005, p. 24). The companies announced March 30 that they have completed submission of the rolling panitumumab BLA...